48
Participants
Start Date
July 16, 2019
Primary Completion Date
June 2, 2020
Study Completion Date
March 30, 2021
LY3295668 Erbumine
oral capsules
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven
Grand Hopital de Charleroi-Site Notre-Dame, Charleroi
AZ Delta, Roeselare
Universitair Ziekenhuis Gent, Ghent
Memorial Sloan Kettering Cancer Center, New York
APHM Hôpital de la Timone, Marseille
University of Pittsburgh Medical Center, Pittsburgh
Centre Georges Francois Leclerc, Dijon
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Levine Cancer Institute- Carolinas Medical Center, Charlotte
Hospital Clinico Universitario Virgen de la Victoria, Málaga
Prisma Health Cancer Institute, Greenville
Institut Bergonie, Bordeaux
H Lee Moffitt Cancer Center, Tampa
Ege University Faculty of Medicine, Izmir
Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain
Hospital Universitario La Fe de Valencia, Valencia
Washington University Medical School, St Louis
Centre de Lutte Contre le Cancer Leon Berard, Lyon
Highlands Oncology Group, Fayetteville
Institut Curie, Paris
Tyler Cancer Center, Tyler
Texas Oncology Fort Worth, Fort Worth
University of Texas MD Anderson Cancer Center, Houston
US Oncology, The Woodlands
Texas Oncology Cancer Center, Austin
Rocky Mountain Cancer Center, Denver
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Dartmouth Hitchcock Medical Center, Lebanon
National Cancer Center Hospital, Chuo-Ku
Severance Hospital Yonsei University Health System, Seoul
Samsung Medical Center, Seoul
Asan Medical Center, Seoul
Institut Catala d'Oncologia, L'Hospitalet de Llobregat
Hospital Universitari Vall d'Hebron, Barcelona
Dr.Abdurrahman Yurtaslan Ankara Oncology Training & Res Hosp, Ankara
Guys/St. Thomas Hospital, London
Royal Marsden Hospital, Sutton
Eli Lilly and Company
INDUSTRY